secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001493152-25-017306
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic regains Nasdaq compliance, achieves $750K in milestones with Proliant & Inzymes
--------------------------------------------------------------------------------

- Regained compliance with Nasdaq market value ($35M) and bid price ($1.00) rules after 10 consecutive days ending Sept 30 & Oct 2, 2025.
- Received $500K milestone from Proliant for recombinant human albumin productivity; payment expected Q4 2025; commercial launch targeted late 2025/early 2026.
- Received $250K milestone payment from Inzymes for dairy enzyme productivity improvements; first enzyme scale-up on track for late 2025 launch.
- Signed term sheet for development of non-animal human alpha-lactalbumin for infant nutrition; sampling of bovine version underway.
- Advancing commercialization of recombinant transferrin and DNase I with ongoing sampling and validation in research/diagnostic markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000149315225017306/0001493152-25-017306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000149315225017306/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-017306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer